交银国际发布研报称，看好康宁杰瑞制药(09966)ADC产品矩阵的巨大全球市场潜力，上调2025-27年收 入预测3-8%，上调目标价至13港元，评级升至"买入"。该行认为，凭借KN026及JSKN003，公司有望实 现在乳腺癌的全线、多亚型覆盖，并拓展其他HER2表达实体瘤的使用，借助差异化布局在HER2赛道拥 有一席之地。 ...

截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康寧傑瑞生物製藥 呈交日期: 2025年12月4日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 II. 已發行股份及/或庫存股份變動 FF301 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09966 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 25,100,000,000 | USD | | 0.000002 USD | | 50,200 | | 增加 / 減少 (-) | | | | 0 | | USD | | 0 | | 本月底結存 | | | 25,100,000,000 | USD | | 0.000002 USD | | 50 ...

Group 1 - The company, Corning Jereh Pharmaceutical-B (09966), announced a share buyback plan [1] - The company will spend HKD 2.457 million to repurchase 236,000 shares [1]

Core Viewpoint - 康宁杰瑞制药-B announced a share buyback on December 1, 2023, spending HKD 2.457 million to repurchase 236,000 shares at a price range of HKD 10.25 to HKD 10.48 per share [1] Summary by Category - **Company Actions** - 康宁杰瑞制药-B executed a buyback of 236,000 shares at a total cost of HKD 2.457 million [1] - The repurchase price per share ranged from HKD 10.25 to HKD 10.48 [1]

Core Viewpoint - Corning Incorporated announced a share buyback plan, intending to repurchase 236,000 shares at a cost of HKD 2.457 million on December 1, 2025 [1] Group 1 - The company plans to spend HKD 2.457 million for the buyback [1] - A total of 236,000 shares will be repurchased as part of this initiative [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康寧傑瑞生物製藥 呈交日期： 2025年12月1日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09966 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔 ...

Group 1 - Corning Incorporated announced the issuance of 146,000 shares due to the exercise of options on November 27, 2025 [1]

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) announced the issuance of 146,000 shares due to the exercise of options on November 27, 2025 [1] Summary by Category - **Company Announcement** - Corning Jereh Pharmaceutical-B will issue 146,000 shares as a result of option exercise [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康寧傑瑞生物製藥 呈交日期： 2025年11月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 09966 | 說明 | 普通股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | 每股發行/出售價 (註4) | | ...

Core Viewpoint - 康宁杰瑞制药-B (09966) announced a share buyback program, indicating confidence in its business outlook and intrinsic value, with a maximum repurchase amount of 30 million HKD [1] Group 1: Share Buyback Announcement - The board of 康宁杰瑞制药 decided on November 7 to repurchase ordinary shares from the open market, with a maximum amount of 30 million HKD [1] - The board believes that the current trading price does not accurately reflect the company's intrinsic value [1] - This buyback is expected to benefit the company and create value for its shareholders [1] Group 2: Previous Buyback Program - In October, 康宁杰瑞制药 announced a plan to repurchase up to 20 million HKD worth of shares [1]